Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3872 publications

Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?

Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?

Journal: Cardiology in review
Published: December 16, 2025

Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.

Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.

Journal: Cardiology in review
Published: December 16, 2025

Mirtazapine for gastrointestinal side effects of glucagon-like peptide-1 receptor agonist therapy in older adults.

Mirtazapine for gastrointestinal side effects of glucagon-like peptide-1 receptor agonist therapy in older adults.

Journal: Endocrine regulations
Published: December 13, 2025

Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.

Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.

Journal: Journal of the American Heart Association
Published: December 11, 2025

Oral Semaglutide in Adults with Overweight or Obesity. Reply.

Oral Semaglutide in Adults with Overweight or Obesity. Reply.

Journal: The New England journal of medicine
Published: December 10, 2025

Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.

Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.

Journal: Neurology
Published: December 10, 2025

Oral Semaglutide in Adults with Overweight or Obesity.

Oral Semaglutide in Adults with Overweight or Obesity.

Journal: The New England journal of medicine
Published: December 10, 2025

Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.

Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.

Journal: BMJ open
Published: December 10, 2025

Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Journal: JAAPA : official journal of the American Academy of Physician Assistants
Published: December 10, 2025

Oral Semaglutide in Adults with Overweight or Obesity.

Oral Semaglutide in Adults with Overweight or Obesity.

Journal: The New England journal of medicine
Published: December 10, 2025

Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.

Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.

Journal: Current medical research and opinion
Published: December 09, 2025

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.

Journal: Annals of internal medicine
Published: December 08, 2025
Showing 1-12 of 3,872

Last Updated: 01/07/2026